Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 25:18:2065-2078.
doi: 10.2147/IDR.S519211. eCollection 2025.

Clinical Features of Anti-Tuberculosis Drug-Induced Liver Injury and Risk Factors for Severe Cases: A Retrospective Study in China

Shuang Zhang  1 , Ningning Dong  1 , Lu Wang  1 , Yu Lu  1 , Xiaoyou Chen  2
Affiliations

Clinical Features of Anti-Tuberculosis Drug-Induced Liver Injury and Risk Factors for Severe Cases: A Retrospective Study in China

Shuang Zhang et al. Infect Drug Resist. .

Abstract

Background: Anti-tuberculosis drug-induced liver injury (ATB-DILI) is a common adverse reaction associated with tuberculosis (TB) treatment, significantly impacting treatment adherence and therapeutic outcomes. However, large-scale studies on hospitalized patients in China remain limited.

Purpose: To characterize the clinical features and liver injury patterns in hospitalized TB patients with ATB-DILI and to identify risk factors associated with severe ATB-DILI.

Methods: We retrospectively reviewed 28,753 hospitalized TB patients at Beijing Chest Hospital from 2014 to 2023. ATB-DILI was diagnosed in 567 patients (2.0%) based on serum biochemical criteria and causality assessment. Demographic, clinical, and laboratory data were analyzed to characterize liver injury types and identify risk factors for severe cases. Subgroup analyses based on liver injury patterns were performed to further evaluate the association between age and severe ATB-DILI.

Results: Overall, 567 cases with ATB-DILI (2.0%) were analyzed. Hepatocellular injury was the most common type (71.4%), followed by cholestatic (13.8%) and mixed (14.8%) injury patterns. Most patients (68.4%) were asymptomatic and diagnosed via routine biochemical monitoring; jaundice occurred in 18.2%. Patients with hepatocellular damage were significantly younger, while those with cholestatic injury were older (p < 0.001). Severe ATB-DILI occurred in 46 patients (8.1%), with advanced age (≥60 years) identified as an independent risk factor (OR = 2.45, 95% CI: 1.33-4.52, p = 0.004). Subgroup analysis showed that this association between age and severe ATB-DILI was significant in the hepatocellular injury type (unadjusted OR = 3.59, 95% CI: 1.61-8.02, p = 0.002), while no statistically significant association was observed in cholestatic or mixed types, which may reflect limited statistical power in these subgroups.

Conclusion: Routine liver function monitoring and age-specific risk assessment are essential for early identification and management of ATB-DILI in hospitalized TB patients.

Keywords: anti-tuberculosis drugs; drug-induced liver injury; hepatotoxicity; risk factors; severe liver injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no commercial or financial relationships that could be perceived as a potential conflict of interest in relation to this research.

Figures

Figure 1
Figure 1
Patient inclusion and exclusion flowchart for ATB-DILI.
Figure 2
Figure 2
Effect of age on severe ATB-Dili according to different types of liver injury. Shown are subgroup-specific odds ratios for all the patients and for those who were hepatocellular, cholestatic, or mixed liver injury. Odds ratios are plotted as squares, the horizontal lines represent 95% confidence intervals. Bold p-values indicate statistical significance (p < 0.05). Post hoc power analysis indicated that the statistical power for detecting associations in the hepatocellular group was 89.7% (or 76.2% after Bonferroni correction), whereas the cholestatic and mixed groups had limited power (23.1% and 34.5%, respectively).
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report, Geneva, Switzerland, 2024.
    1. Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial. Clin Infect Dis. 2020;70(12):2675–2682. doi:10.1093/cid/ciz732 - DOI - PMC - PubMed
    1. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol Res. 2005;51(4):353–358. doi:10.1016/j.phrs.2004.10.009 - DOI - PubMed
    1. Gülbay BE, Gürkan OU, Yildiz OA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100(10):1834–1842. doi:10.1016/j.rmed.2006.01.014 - DOI - PubMed
    1. Tweed CD, Wills GH, Crook AM, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018;16(1):46. doi:10.1186/s12916-018-1033-7 - DOI - PMC - PubMed

LinkOut - more resources